Executive Summary The patent is the fundamental unit of value in the pharmaceutical industry. A single compound patent on a […]

Part I: Why This Matters — The Stakes of Drug Patent Intelligence The Numbers Behind a Bad Search The Tufts

A deep-dive analysis for pharma/biotech IP teams, R&D leads, and institutional investors. Introduction: How a Single Negotiation Rewires a Drug’s

Why the Cheapest Generic Manufacturer Usually Loses The dominant assumption inside generic pharma for the past three decades has been

1. Why This Analysis Exists: The $234 Billion Question Nobody Is Answering Precisely Between 2025 and 2034, 118 biologic medicines

I. Executive Summary and Scope The $1.6 trillion global pharmaceutical industry runs on a single underlying premise: time-limited exclusivity justifies

Executive Summary Generic drugs now account for roughly 90% of all U.S. prescriptions filled, yet constitute less than 13% of

A deep-dive for pharma/biotech IP strategists, pipeline analysts, and buy-side investors. Part I: The Japanese Pharmaceutical Market Sizing Up the

The pharmacy counter is one of the most consequential decision points in American healthcare. A prescription that a physician deemed